Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pharmacologic Treatment of Posttraumatic Stress Disorder: A Focus on Antipsychotic Use

Pharmacologic Treatment of Posttraumatic Stress Disorder: A Focus on Antipsychotic Use To review the literature on the pharmacologic treatment of posttraumatic stress disorder (PTSD), with a focus on reports of antipsychotic use for this illness. A MEDLINE search (1966-Oct 2002) for English only articles about pharmacologic treatment of PTSD. Antipsychotic medications are being used with some frequency for PTSD. There are few studies and scant evidence to recommend the traditional antipsychotics. There are a number of reports (mostly case reports and open trials) in which atypical antipsychotics improved sleep and decreased the frequency of nightmares and flashbacks. Some studies showed global improvement across symptom clusters. The newer atypical antipsychotics show promise for the treatment of PTSD, mainly ameliorating intrusive symptoms. The paucity of double-blind studies prevents firm conclusions, however, this class of medications may be useful particularly for refractory symptoms. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Pharmacologic Treatment of Posttraumatic Stress Disorder: A Focus on Antipsychotic Use

Download PDF
9 pages

Loading next page...
 
/lp/springer-journals/pharmacologic-treatment-of-posttraumatic-stress-disorder-a-focus-on-rjb09VS111
Publisher
Springer Journals
Copyright
Copyright © 2003 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/B:ACLI.0000008173.01153.4e
Publisher site
See Article on Publisher Site

Abstract

To review the literature on the pharmacologic treatment of posttraumatic stress disorder (PTSD), with a focus on reports of antipsychotic use for this illness. A MEDLINE search (1966-Oct 2002) for English only articles about pharmacologic treatment of PTSD. Antipsychotic medications are being used with some frequency for PTSD. There are few studies and scant evidence to recommend the traditional antipsychotics. There are a number of reports (mostly case reports and open trials) in which atypical antipsychotics improved sleep and decreased the frequency of nightmares and flashbacks. Some studies showed global improvement across symptom clusters. The newer atypical antipsychotics show promise for the treatment of PTSD, mainly ameliorating intrusive symptoms. The paucity of double-blind studies prevents firm conclusions, however, this class of medications may be useful particularly for refractory symptoms.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Oct 11, 2004

References

  • Trauma: Prevalence, impairment, service use, and cost
    Solomon, S; Davidson, JRT
  • Posttraumatic stress disorder: Epidemiology and health-related considerations
    Hidalgo, RD; Davidson, JRT
  • Posttraumatic stress disorder: The burden to the individual and to society
    Kessler, RC
  • Suicidal behavior after severe trauma, Pt 1: PTSD diagnoses, psychiatric comorbidity, and assessments of suicidal behavior
    Ferrada-Noli, M; Asberg, M; Ormstad, K; Lundin, T; Sundbom, E
  • Traumatic events and posttraumatic stress disorder in an urban population of young adults
    Breslau, N; Davis, GC; Andreski, P; Peterson, E
  • Trauma and posttraumatic stress disorder in the community. The 1996 Detroit area survey of trauma
    Breslau, N; Kessler, RC; Chilcoat, HD; Schultz, LR; Davis, GC; Andreski, P
  • Posttraumatic stress disorder in the National Comorbidity Survey
    Kessler, RC; Sonnega, A; Bromet, E; Hughes, M; Nelson, CB
  • The epidemiology of posttraumatic stress disorder: What is the extent of the problem?
    Breslau, N
  • Posttraumatic stress disorder in the community: An epidemiological study
    Davidson, JR; Hughes, D; Blazer, DG; George, LK
  • Previous exposure to trauma and PTSD effects of subsequent trauma: Results from the Detroit Area Survey of Trauma
    Breslau, N; Chilcoat, HD; Kessler, RC; Davis, GC
  • Risk factors for DSMIIIR PTSD: Findings from the National Comorbidity Survey
    Bromet, E; Sonnega, A; Kessler, RC
  • Vietnam Experience Study: Psychological and Neuropsychological Evaluation
  • Pharmacotherapy of posttraumatic stress disorder: Treatment options, long-term follow-up, and predictors of outcome
    Davidson, JRT
  • Posttraumatic stress disorder: A review of psychobiology and pharmacotherapy
    Hageman, I; Andersen, HS; Jorgensen, MB
  • Treatment of posttraumatic stress disorder
    Cyr, M; Farrar, K
  • Pharmacotherapy of posttraumatic stress disorder
    Stein, DJ; Zungu-Dirwayi, N; van der Linden, GJH; Seedat, S
  • Understanding and treating PTSD: Past, present, and future
    Tucker, P; Trautman, R
  • Pharmacotherapy for posttraumatic stress disorder: Beyond the SSRIs
    Connor, KM; Davidson, JRT
  • Consensus statement on posttraumatic stress disorder from the international consensus group on depression and anxiety
    Ballenger, JC; Davidson, JRT; Lecrubier, Y; Nutt, DJ; Foa, EB; Kessler, RC; McFarlane, AC; Shalev, AY
  • Kindling versus quenching: Implications for the evolution and treatment of in posttraumatic stress disorder
    Post, RM; Weiss, SRB; Smith, M; Li, H; McCann, U
  • Posttraumatic stress disorder in Vietnam veterans: Clinical and EEG findings; possible therapeutic effects of carbamazepine
    Wolfe, ME; Alavi, A; Mosnaim, AD
  • Preliminary study of carbamazepine in posttraumatic stress disorder
    Lipper, S; Davidson, JRT; Grady, TA; Edinger, JD; Hammett, EB; Mahorney, SL; Cavenar, JO
  • Valproate in combat-related posttraumatic stress disorder
    Fesler, FA
  • Divalproex in posttraumatic stress disorder: an open-label clinical trial
    Clark, RD; Canive, JM; Calais, LA; Qualls, CR; Tuason, VB
  • Low dose lithium carbonate in the treatment of posttraumatic stress disorder: Brief communication
    Kitchner, I; Greenstein, R
  • Topiramate in posttraumatic stress disorder: Preliminary clinical observations
    Berlant, JL
  • Open-label topirimate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: A preliminary report
    Berlant, JL; van Kammen, DP
  • A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder
    Hertzberg, MA; Butterfield, MI; Feldman, ME; Beckham, JC; Sutherland, SM; Connor, KM; Davidson, JR
  • Gabapentin in PTSD: A retrospective clinical series of adjunctive therapy
    Hamner, MB; Bodrick, PS; Labbate, LA
  • Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment
    Braun, P; Green, D; Dasberg, H; Lerer, B
  • Treament of recent trauma survivors with bensodiazepines: A prospective study
    Gelpin, E; Bonne, O; Peri, T; Brandes, D; Shalev, AY
  • Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced post-traumatic stress disorder
    Risse, SC; Whitters, A; Burke, J; Chen, S; Scurfield, RM; Raskind, MA
  • Propranolol treatment for childhood post-traumatic stress disorder, acute type: A pilot study
    Famularo, R; Kinscherff, R; Fenton, T
  • Nerobiological and Clinical Consequences of Stress: From Normal Adaptation to PTSD
    Friedman, MJ; Southwick, SM
  • Clonidine in Cambodian patients with posttraumatic stress disorder
    Kinzie, JD; Leung, P
  • The alpha adrenergic antagonist prazosin improves sleep and nightmares in civilian trauma post-traumatic stress disorder
    Taylor, F; Raskind, MA
  • The alpha adrenergic antaonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: A report of four cases
    Raskind, MA; Dobie, DJ; Kanter, ED; Petrie, EC; Thompson, CE; Peskind, ER
  • Diagnostic and psychopharmacological treatment characteristics of 536 inpatients with post-traumatic stress disorder
    Faustman, WO; White, PA
  • Posttraumatic stress disorder: Characteristics and pharmacological response in the veteran population
    Birklimer, LJ; DeVane, CL; Muniz, CE
  • Pharmacotherapy for PTSD
    Ciccone, PE; Amzarek, A; Weisbrot, M; Greenstein, RA; Olsen, K; Zimmerman, J
  • Neuroleptic use in the treatment of posttraumatic stress disorder
    Sernyak, MJ; Kosten, TR; Fontana, A; Rosenheck, R
  • Posttraumatic stress disorder following combat exposure: Clinical features and psychopharmacological treatment
    Bleich, A; Siegel, B; Garb, R; Lerer, B
  • Use of thioridazine in posttraumatic stress disorder
    Dillard, ML; Bendfeldt, F; Jernigan, P
  • Risperidone in the treatment of acute stress disorder in physically traumatized inpatients
    Eidelman, I; Seedat, S; Stein, DJ
  • Risperidone in PTSD
    Leyba, CM
  • Risperidone as an adjunct therapy for posttraumatic stress disorder
    Krashin, D; Oates, EW
  • Risperidone effects on irritable aggression in posttraumatic stress disorder
    Monnelly, EP; Ciraulo, DA
  • A randomized, controlled trial of risperidone for psychotic features in PTSD
    Hamner, MB; Ulmer, HG; Faldowski, RA; Frueh, BC; Twomey, TJ; Tyson, C; Lorberbaum, JP; Teneback, CC; Huber, MG; Arana, GW
  • Olanzapine treatment for posttraumatic stress disorder: An open-label study
    Petty, F; Brannan, S; Casada, J; Davis, LL; Gajewski, V; Kramer, GL; Stone, RC; Teten, AL; Worchel, J; Young, KA
  • Olanzapine in the treatment of posttraumatic stress disorder
    Butterfield, M; Becker, ME; Connor, KM; Sutherland, S; Churchill, LE; Davidson, JRT
  • Adjunctive olanzapine for SSRI-resistant combat-related PTSD: A double-blind, placebo-controlled study
    Stein, MB; Kline, NA; Matloff, JL
  • Olanzapine for nightmares and sleep disturbance in posttraumatic stress disorder
    Labatte, L; Douglas, S
  • Treatment of posttraumatic stress disorder with olanzapine
    Prior, TI
  • Clozapine treatment for a veteran with comorbid psychosis and PTSD
    Hamner, MB
  • What might the psychobiology of posttraumatic stress disorder teach us about future approaches to pharmacotherapy?
    Friedman, MJ
  • Neurobiological and Clinical Consequences of Stress: From Normal Adaptation to PTSD
    Southwick, SM; Yehuda, R; Morgan, CA
  • Hypothalamic-pituitary-adrenal axis dysregulation in sexually abused girls
    DeBellis, MD; Chrousos, GP; Dorn, LD; Burke, L; Helmers, K; Kling, MA; Trickett, PK; Putnam, FW
  • Post-traumatic stress disorder and serotonin: New directions for research and treatment
    Davis, LL; Suris, A; Lambert, MT; Heinberg, C; Petty, F
  • Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol
    Tollefson, GD; Sanger, TM; Lu, Y; Thieme, ME
  • Understanding and treating PTSD: Past, present, and future
    Tucker, P; Trautman, R
  • A novel augmentation strategy for treating resistant major depression
    Shelton, RC; Tollefson, GD; Tohen, M; Stahl, S; Gannon, KS; Jacobs, TG; Buras, WR; Bymaster, FP; Zhang, W; Spencer, KA; Feldman, PD; Meltzer, HY
  • Adjunctive use of olanzapine in mood disorders: Five case reports
    Weisler, RH; Ahearn, EP; Davidson, JT; Wallace, R
  • Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol
    Tollefson, GD; Sanger, TM; Lu, Y; Thieme, ME
  • Olanzapine response in psychotic depression
    Rothschild, AJ; Bates, KS; Boehringer, KL; Syed, A
  • Progress in pharmacotherapy of borderline disorders
    Soloff, PH; George, A; Nathan, RS; Schulz, PM; Ulrich, RF; Perel, JM
  • Pharmacotherapy of borderline personality disorder
    Cowdry, RW; Gardner, DL
  • Efficacy of olanzapine in social anxiety disorder: A pilot study
    Barnett, SD; Kramer, ML; Casat, CD; Connor, KM; Davidson, JR
  • Psychobiological mechanisms of posttraumatic stress disorder
    Charney, DS; Deutch, AY; Krystal, JH; Southwick, SM; Davis, M
  • Selective activation of the mesocortical dopamine system by stress
    Thierry, AM; Tassin, TP; Blanc, G; Glowinski, J
  • Effect of noxious tail pinch on the discharge rate of mesocortical and mesolimbic dopamine neurons: Selective activation of the mesocortical system
    Mantz, J; Thierry, AM; Glowinski, J
  • Urinary catecholamine excretion and severity of PTSD symptoms in Vietnam combat veterans
    Yehuda, R; Southwick, S; Giller, EL; Ma, X; Mason, JW
  • Elevated plasma dopamine in post-traumatic stress disorder: A preliminary report
    Hamner, M; Diamond, BI
  • Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents
    Marx, CE; VanDoren, MJ; Duncan, GE; Lieberman, JA; Morrow, AL
  • Olanzapine increases allopregnanolone in the rat cerebral cortex
    Marx, CE; Duncan, GE; Gilmore, JH; Lieberman, JA; Morrow, AL
  • Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine
    Uzunova, V; Sheline, Y; Davis, JM; Rasmusson, A; Uzunov, DP; Costa, E; Guidotti, A
  • Effects of antidepressant treatment on neuroactive steroids in major depression
    Romeo, E; Str, A; Spalletta, G; di Michele, F; Hermann, B; Hols-boer, F; Pasini, A; Rupprecht, R
  • Anxiolytic activity of an endogenous adrenal steroid
    Crawley, JN; Glowa, JR; Majewska, MD; Paul, SM
  • Anxiolytic activity of the progesterone metabolite 5alpha-pregnan-3alpha-ol-20-one
    Wieland, S; Lan, NC; Mirasedeghi, S; Gee, KW